ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial.
Soria
Jean-Charles
JC
D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor; D004247:DNA / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000096:biosynthesis / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008495:Medical Oncology / Q000379:methods*; D011379:Prognosis; D011446:Prospective Studies; D012333:RNA, Messenger / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D004247:DNA; C071447:ERCC1 protein, human; D004720:Endonucleases